| Bioactivity | Palifermin is the recombinant human keratinocyte growth factor (KGF). Palifermin induces cells growth. Palifermin shows antimucotoxic. Palifermin can be used to decrease the oral mucosal injury induced by cytotoxic therapy[1][2][3]. |
| Invitro | Palifermin (0-100 ng/mL; 48 h) stimulates the growth of TE-8, TE-11 cells[1]. Cell Proliferation Assay[1] Cell Line: |
| In Vivo | Palifermin (10 mg/kg for single dose or 3 mg/kg for 3 times; daily for 3 days) reduces diarrhea and increases survival following Irinotecan treatment in tumor-bearing DA rats[2].Palifermin (5 mg/kg; s.c.) shows effectiveness on oral mucositis induced by fractionated irradiation[3]. Animal Model: |
| Name | Palifermin |
| CAS | 162394-19-6 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Spielberger R, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004 Dec 16;351(25):2590-8. [2]. Yoshino M, et al. Expression and roles of keratinocyte growth factor and its receptor in esophageal cancer cells. Int J Oncol. 2007 Oct;31(4):721-8. [3]. Dörr W, et al. Effects of keratinocyte growth factor (palifermin) administration protocols on oral mucositis (mouse) induced by fractionated irradiation. Radiother Oncol. 2005 Apr;75(1):99-105. |